دورة المؤشرنت للتحليل الفني
50 دينار كويتي
للمتابعة : سهم VASO
- بادئ الموضوع investor
- تاريخ البدء
investor
عضو نشط
- التسجيل
- 11 سبتمبر 2001
- المشاركات
- 326
صافي خسارة الشركة 0.3 مليون دولار وهذه النتيجة أفضل بكثير من السابق مع زيادة في المبيعات مما يعطي إشارة لتحسن وضع الشركة واحتمال قوي لصعود سهمها في الفترة المقبلة
http://biz.yahoo.com/bw/031015/155857_1.html
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: Vasomedical, Inc.
Vasomedical Reports First Quarter Fiscal 2004 Results
Wednesday October 15, 4:05 pm ET
WESTBURY, N.Y.--(BUSINESS WIRE)--Oct. 15, 2003--Vasomedical, Inc. (Nasdaq SmallCap:VASO - News) a leader in the field of noninvasive treatment and management of cardiovascular diseases, today announced operating and financial results for the first quarter of fiscal year 2004 ended August 31, 2003.
For the first quarter ended August 31, 2003, total revenues were $5.4 million, a 20% increase over total revenues of $4.5 million for the comparable period last year. The increase was due primarily to an increase in EECP® equipment unit sales for the quarter, which was partially offset by a decline in the average unit selling prices due to increased competition and, to a lesser extent, a shift in the mix of products sold during the quarter to a higher proportion of the lower-priced MC2 models compared to last year. In addition, revenue from equipment rentals and services increased nearly 91% to $0.6 million in the first quarter of fiscal 2004 compared to $0.3 million in the first quarter a year ago.
The net loss for the first quarter ended August 31, 2003, was approximately $0.3 million and the loss was less than one cent per share. This compares to a loss in first quarter ended August 31, 2002 of $4.2 million, or a loss of $0.07 per share. The reduction in net loss reflects, among other things, the higher total revenue; improved gross profit margins; the impact of tighter cost controls and reduced expenditures; and the absence of special one-time charges recorded in the first quarter of the prior fiscal year totaling approximately $3.2 million.
Gregory D. Cash, Vasomedical's President and Chief Executive Officer, noted that the Company is, "continuing to invest in a variety of marketing programs intended to increase awareness and acceptance of EECP therapy in the marketplace. This includes an ongoing direct mail campaign targeting U.S. cardiologists, a physician-directed advertising campaign in major cardiovascular medical journals, sponsorship of regional educational seminars for physicians and attendance at major cardiovascular congresses and symposia. We continue to grow and train our domestic field selling organization, which now consists of 23 direct sales people, nine clinical specialists and three independent sales agents."
"Several papers have recently been published or accepted for publication in Clinical Cardiology, the American Journal of Cardiology, Cardiology and Heart, indicating our on-going support for clinical research. In addition, seven papers or posters on EECP were presented at the European Society of Cardiology, TCT and Heart Failure Society of America meetings this fall."
"Finally, looking toward longer-term growth drivers, the PEECH(TM) trial has now reached the 85% enrollment mark. At this rate, enrollment should be complete by the end of the calendar year, positioning Vasomedical to meet the previously identified time schedule for submitting data to CMS. Accordingly, we maintain our belief that CMS could establish a reimbursement policy for the heart failure indication in 2005. Also, the increased Medicare reimbursement rates for patients with disabling angina pectoris that took effect earlier in the calendar year make the provision of EECP therapy increasingly attractive to potential providers in the face of declining reimbursement for other cardiovascular procedures."
"The first quarter showed improvement over the prior year's quarter, and we are working hard to increase our sales in future quarters. Our goals continue to be growing revenue and investing in the continued development of the EECP business over the coming years. Our primary objectives in achieving these goals are further expanding reimbursement for EECP as well as increasing the awareness and acceptance of EECP in the U.S. market and, on a more limited basis, the international market. We feel positive about the Company's ability to achieve these goals over the long term," concluded Cash.
As previously announced, the Company will host a conference call to discuss first quarter 2003 results. Mr. Gregory D. Cash, President and Chief Executive Officer, and Mr. Thomas Fry, Chief Financial Officer, of Vasomedical will host the call.
http://biz.yahoo.com/bw/031015/155857_1.html
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: Vasomedical, Inc.
Vasomedical Reports First Quarter Fiscal 2004 Results
Wednesday October 15, 4:05 pm ET
WESTBURY, N.Y.--(BUSINESS WIRE)--Oct. 15, 2003--Vasomedical, Inc. (Nasdaq SmallCap:VASO - News) a leader in the field of noninvasive treatment and management of cardiovascular diseases, today announced operating and financial results for the first quarter of fiscal year 2004 ended August 31, 2003.
For the first quarter ended August 31, 2003, total revenues were $5.4 million, a 20% increase over total revenues of $4.5 million for the comparable period last year. The increase was due primarily to an increase in EECP® equipment unit sales for the quarter, which was partially offset by a decline in the average unit selling prices due to increased competition and, to a lesser extent, a shift in the mix of products sold during the quarter to a higher proportion of the lower-priced MC2 models compared to last year. In addition, revenue from equipment rentals and services increased nearly 91% to $0.6 million in the first quarter of fiscal 2004 compared to $0.3 million in the first quarter a year ago.
The net loss for the first quarter ended August 31, 2003, was approximately $0.3 million and the loss was less than one cent per share. This compares to a loss in first quarter ended August 31, 2002 of $4.2 million, or a loss of $0.07 per share. The reduction in net loss reflects, among other things, the higher total revenue; improved gross profit margins; the impact of tighter cost controls and reduced expenditures; and the absence of special one-time charges recorded in the first quarter of the prior fiscal year totaling approximately $3.2 million.
Gregory D. Cash, Vasomedical's President and Chief Executive Officer, noted that the Company is, "continuing to invest in a variety of marketing programs intended to increase awareness and acceptance of EECP therapy in the marketplace. This includes an ongoing direct mail campaign targeting U.S. cardiologists, a physician-directed advertising campaign in major cardiovascular medical journals, sponsorship of regional educational seminars for physicians and attendance at major cardiovascular congresses and symposia. We continue to grow and train our domestic field selling organization, which now consists of 23 direct sales people, nine clinical specialists and three independent sales agents."
"Several papers have recently been published or accepted for publication in Clinical Cardiology, the American Journal of Cardiology, Cardiology and Heart, indicating our on-going support for clinical research. In addition, seven papers or posters on EECP were presented at the European Society of Cardiology, TCT and Heart Failure Society of America meetings this fall."
"Finally, looking toward longer-term growth drivers, the PEECH(TM) trial has now reached the 85% enrollment mark. At this rate, enrollment should be complete by the end of the calendar year, positioning Vasomedical to meet the previously identified time schedule for submitting data to CMS. Accordingly, we maintain our belief that CMS could establish a reimbursement policy for the heart failure indication in 2005. Also, the increased Medicare reimbursement rates for patients with disabling angina pectoris that took effect earlier in the calendar year make the provision of EECP therapy increasingly attractive to potential providers in the face of declining reimbursement for other cardiovascular procedures."
"The first quarter showed improvement over the prior year's quarter, and we are working hard to increase our sales in future quarters. Our goals continue to be growing revenue and investing in the continued development of the EECP business over the coming years. Our primary objectives in achieving these goals are further expanding reimbursement for EECP as well as increasing the awareness and acceptance of EECP in the U.S. market and, on a more limited basis, the international market. We feel positive about the Company's ability to achieve these goals over the long term," concluded Cash.
As previously announced, the Company will host a conference call to discuss first quarter 2003 results. Mr. Gregory D. Cash, President and Chief Executive Officer, and Mr. Thomas Fry, Chief Financial Officer, of Vasomedical will host the call.
دورة المؤشرنت للتحليل الفني
50 دينار كويتي